AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAM

Amgen Inc., a leading biotechnology company, announced today that it will be hosting a webcast to discuss the results of the Maritide Phase 2 clinical trial and provide updates on its development program. Maritide is a promising drug candidate for the treatment of a certain type of cancer, and the Phase 2 results are highly anticipated by investors and the medical community.

During the webcast, Amgen's top executives and key researchers will present the data collected from the clinical trial, highlighting the drug's effectiveness and safety profile. They will also discuss the next steps in the development program, including plans for Phase 3 trials and potential regulatory submissions.

Investors and healthcare professionals are eagerly waiting for these results, as the success of Maritide could have a significant impact on Amgen's future revenue and growth prospects. Analysts expect that positive Phase 2 results could further boost the company's stock price, which has already shown strong performance in recent months.

However, it is important to note that investing in biotechnology stocks can be highly volatile and risky. Therefore, it is recommended to seek the advice of professionals, such as those from Stocks Prognosis, who specialize in analyzing market trends and providing accurate forecasts.

To stay informed about the latest updates and make well-informed investment decisions, considering seeking guidance from professionals like Stocks Prognosis.